Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
FAIL · Does not pass the screen
130.91 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 16:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning political selling, disclosed 2026-09-29
Options put/call open interest 0.09, read 2026-10-28
Ethical does not pass the values gate
Price130.91 USD
Fair value130.00
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Accumulation130.91+0.0% to today ✓Markup gives way to Accumulation after a 7% rise in 11 days
2026-10-21Read Markup122.50+6.9% to today ✓Accumulation gives way to Markup after a 15% rise in 3 weeks
2026-10-02Read Accumulation106.94+22.4% to today ✓Markup gives way to Accumulation first Accumulation read since August
2026-08-31Read Markup109.32+19.7% to today ✓Accumulation gives way to Markup after a 31% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Halozyme Therapeutics, Inc. holds its Accumulation at $130.91. Consolidating, no directional conviction, held for 39 days.
As held on the ledger · 2026-10-30
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 39 days
Price at the screen
$130.91
Valuation
35.82 trailing · 11.47 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.88
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
84.85%
Below 33%
Interest-bearing debt is 84.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.36%
Below 33%
Cash held in interest-bearing accounts and securities is 0.4% of assets, under the one-third limit.
Pass
Receivables
22.50%
Below 49%
Money owed to the company is 22.5% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Halozyme Therapeutics,'s business is in a permissible area, but its interest-bearing debt is about 85% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HALO's ethical verdict changes
Today HALO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 0.7% above the base estimate.
Where our models see it going: fair-value estimate $130.00, with a range of $130.00 to $261.82, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Enzyme tech with standout numbers yet no call
Think of a small enzyme that helps big drug companies get their medicines working faster inside the body. Halozyme has built a business around that idea and it shows in the results. Revenue is rising 42 percent a year, profit margins sit at 23 percent and return on equity hits 99 percent while the forward multiple is just 7.9 times.
Those figures would normally put the stock on our list. Yet the opportunity rating is none. The market already prices in solid growth and the ethical screen passes, so nothing extra stands out once the headline numbers are stripped away.
Risk sits in the usual biotech unknowns around pipeline delivery and competition. A single missed approval or fresh rival enzyme could reset the low multiple quickly. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HALO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$125.63+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$125.63+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$125.63+2.6%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$122.50+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter.
2026-10-21Markup · changed$122.50+10.9%Entry 8
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter.
2026-10-14Accumulation$110.42+3.3%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84. Insiders have been net sellers over the past quarter.
2026-08-31Markup · changed$109.32+31.2%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 31.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 19.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (10 analysts) rates it buy, with a mean price target of $84.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
